Avidity Biosciences, Inc.(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RNA Avidity Biosciences, Inc.

交易中 12-16 11:40:44 EST

71.92

+0.06

+0.08%

最高71.93	最低71.75	成交量55.59万
今开71.80	昨收71.86	日振幅0.24%
总市值108.36亿	流通市值81.26亿	总股本1.51亿
成交额3,994万	换手率0.49%	流通股本1.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Avidity Biosciences, Inc.","latestPrice":71.915,"timestamp":1765903225770,"preClose":71.86,"halted":0,"volume":555887,"delay":0,"floatShares":112999999,"shares":150675742,"eps":-4.185146,"marketStatus":"交易中","change":0.055,"latestTime":"12-16 11:40:44 EST","open":71.8,"high":71.925,"low":71.75,"amount":39937679.27952,"amplitude":0.002435,"askPrice":71.92,"askSize":385,"bidPrice":71.91,"bidSize":954,"shortable":3,"etf":0,"ttmEps":-4.185146,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765918800000},"marketStatusCode":2,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":71.86,"preHourTrading":{"tag":"盘前","latestPrice":71.83,"preClose":71.86,"latestTime":"09:29 EST","volume":2657,"amount":190859.11192,"timestamp":1765895399999},"postHourTrading":{"tag":"盘后","latestPrice":71.86,"preClose":71.86,"latestTime":"19:51 EST","volume":246823,"amount":17736692.9868,"timestamp":1765846300595},"volumeRatio":0.765822,"impliedVol":0.3041,"impliedVolPercentile":0.132},"requestUrl":"/m/hq/s/RNA/wiki","defaultTab":"wiki","newsList":[{"id":"2588701014","title":"Wave Life Sciences Ltd.盘中异动 股价大跌5.03%报7.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701014?lang=zh_cn&edition=full","pubTime":"2025-12-02 04:08","pubTimestamp":1764619730,"startTime":"0","endTime":"0","summary":"北京时间2025年12月02日04时08分，Wave Life Sciences Ltd.股票出现波动，股价快速跳水5.03%。截至发稿，该股报7.37美元/股，成交量97.1002万股，换手率0.58%，振幅3.67%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为1.63%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。其项目针对罕见和普遍的疾病，包括 α-1 抗胰蛋白酶缺乏症、肥胖症、杜氏肌营养不良症和亨廷顿病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202040850a4c6631b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202040850a4c6631b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","WVE","BK4585","RNA","IE0009354923.USD","BK4505","BK4139"],"gpt_icon":0},{"id":"2586244925","title":"诺华同意收购RNA疗法创新企业Avidity Biosciences，以强化其后期阶段的神经科学管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2586244925","media":"动脉网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586244925?lang=zh_cn&edition=full","pubTime":"2025-11-25 12:36","pubTimestamp":1764045360,"startTime":"0","endTime":"0","summary":"诺华宣布收购RNA疗法企业Avidity Biosciences，收购将在Avidity分拆早期心脏疾病项目后进行。此次收购契合诺华深耕神经科学的战略，有望填补遗传性疾病治疗空白，扩展公司管线。Avidity项目包含潜在同类首创、处于临床试验后期阶段的疾病修饰疗法，适用于多种罕见神经肌肉疾病。基于诺华专业经验及商业化能力，此次收购有望打造行业领先研发管线，AOC平台将单抗组织特异性与寡核苷酸精准调控结合，有望改变疾病进程，对患者生活产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125125311977ddcf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125125311977ddcf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RNA","IE0002141913.USD","BK4578","BK4588","BK4505","BK4139","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0009354923.USD","NVS","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4007","IE00B4R5TH58.HKD","LU0211331839.USD","IE0009355771.USD","BK4585","BK4532","LU0070302665.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2585632444","title":"石药集团(01093)：双链小干扰RNA药物(SYH2061注射液)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585632444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585632444?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:20","pubTimestamp":1763979613,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主研发的化学1类新药双链小干扰RNA药物已获得美国食品药品监督管理局批准，可在美国开展临床试验。该产品是一款通过偶联乙酰半乳糖胺实现肝脏靶向递送的siRNA药物，以皮下给药的方式靶向补体蛋白C5，能有效降低C5水平。临床前研究显示，该产品在药物活性和药效持续性方面均优于同类型siRNA产品，展现出药物作用效果持久、安全性良好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288170.HKD","LU1008478684.HKD","01093","IE00B543WZ88.USD","LU1226287875.USD","LU1328277881.USD","LU1226287792.SGD","IE00BZ08YT58.USD","LU0501845795.SGD","LU1960683339.HKD","LU1226288253.USD","IE00BZ08YR35.GBP","LU1813983027.USD","LU1951186391.HKD","IE0008369823.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU1993786604.SGD","BK4585","LU2039709279.SGD","BK4139","BK4505","IE00B5MMRT66.SGD","BK4588","LU0314109678.HKD","LU1807302812.USD","HK0000165453.HKD","LU1226287529.USD","LU0072913022.USD","LU1152091754.HKD","SG9999004220.SGD","RNA","LU0880133367.SGD","BK1515","IE0009354923.USD","LU0067412154.USD","IE0008368742.USD","LU1152091168.USD","BK1191","LU0140636845.USD","BK1521","LU0315179316.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2585431995","title":"港股异动 | MIRXES-B(02629)早盘涨近8% 携手沃森深耕东盟市场 共建RNA精准医疗创新体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2585431995","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585431995?lang=zh_cn&edition=full","pubTime":"2025-11-24 09:45","pubTimestamp":1763948732,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，MIRXES-B早盘涨近8%，截至发稿，涨2.48%，报53.8港元，成交额1829.42万港元。此次合作标志着精准诊断领军企业与顶尖疫苗研发企业实现战略协同，为构建以RNA为核心的预防及精准医疗平台奠定坚实基础。值得注意的是，今年10月，核心产品GASTROClear经中国国家药品监督管理局批准上市，成为全球首款也是目前唯一获批用于胃癌筛查的分子诊断IVD产品。此次获批意味着公司正式进入中国庞大的胃癌筛查市场，成为短期内最重要的业绩催化剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02629","BK4588","BK4505","RNA","BK1161","BK4139","BK4585","IE0009354923.USD"],"gpt_icon":0},{"id":"2585994111","title":"港股异动 | MIRXES-B(02629)午后涨超5% 携手沃森生物创建以RNA为中心的预防及精准医疗平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2585994111","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585994111?lang=zh_cn&edition=full","pubTime":"2025-11-21 13:43","pubTimestamp":1763703822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，MIRXES-B午后涨超5%，截至发稿，涨3.44%，报52.55港元，成交额3273.41万港元。消息面上，MIRXES公布，公司近期与云南沃森生物技术订立谅解备忘录，订约方同意就创建以RNA为中心的预防及精准医疗平台建立战略合作伙伴关系，并涵盖共同开发、临床试验及注册以及销售及分销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","300142","IE0009354923.USD","BK0239","BK4505","BK0070","BK4139","02629","BK4585","BK0077","BK4588","RNA","BK1161"],"gpt_icon":0},{"id":"1140113828","title":"诺华预计2025-2030年销售复合年增长率为+5-6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140113828","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140113828?lang=zh_cn&edition=full","pubTime":"2025-11-20 14:17","pubTimestamp":1763619458,"startTime":"0","endTime":"0","summary":"11月20日（路透社） - 诺华制药发布消息称，预计2025-2030年的销售复合年增长率将达到+5-6%，长期增长受益于30多项潜在高价值的管线资产。*KISQALI和SCEMBLIX的高峰销售指导上调；诺华目前拥有八项风险降低的市场在售资产，预计高峰销售潜力在30亿至100亿美元之间。*展望：预计到2029年将恢复至40%以上的利润率。*计划收购Avidity Biosciences预计将在2026年上半年完成。*KISQALI的销售指导从80亿美元上调至100亿美元以上；SCEMBLIX的销售指导从30亿美元上调至40亿美元以上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RNA","BK4139","BK4505","BK4588","IE0009354923.USD"],"gpt_icon":0},{"id":"1171191887","title":"Avidity Biosciences宣布美国受管制接入计划（MAP）以用于研究性疗法Del-Zota于Dmd44","url":"https://stock-news.laohu8.com/highlight/detail?id=1171191887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171191887?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:14","pubTimestamp":1763561655,"startTime":"0","endTime":"0","summary":"Avidity Biosciences宣布美国受管制接入计划（MAP）以用于研究性疗法Del-Zota于Dmd44","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","IE0009354923.USD","BK4139","BK4585","RNA"],"gpt_icon":0},{"id":"2584891934","title":"佰金生命科学(01466)附属拟入股投资优环生物 打造全球领先的环状RNA(circ RNA)技术研发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2584891934","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584891934?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:36","pubTimestamp":1763541371,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰金生命科学 公布，公司间接全资附属公司北京佰金生物科技有限公司与优环(苏州)生物医药科技有限公司签订策略合作框架协议，据此，北京佰金将透过认购优环生物股权的方式对优环生物进行投资，旨在打造全球领先的环状RNA技术研发平台并借助此平台，深化细胞治疗领域的技术创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK4585","BK4588","BK4139","01466","IE0009354923.USD","BK1227","RNA"],"gpt_icon":0},{"id":"2584957390","title":"Wave Life Sciences Ltd.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584957390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584957390?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:04","pubTimestamp":1763481852,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日00时04分，Wave Life Sciences Ltd.股票出现波动，股价快速跳水5.03%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为0.38%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000412950c86ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000412950c86ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BK4585","WVE","BK4588","RNA","BK4007","IE0009354923.USD"],"gpt_icon":0},{"id":"2584982161","title":"MIRXES-B(02629)与沃森订立谅解备忘录 拟创建以RNA为中心的预防及精准医疗平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2584982161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584982161?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:33","pubTimestamp":1763454810,"startTime":"0","endTime":"0","summary":"智通财经APP讯，MIRXES-B 公布，公司近期与云南沃森生物技术股份有限公司(沃森)订立了一份谅解备忘录，据此，订约方已同意发挥各自的互补优势，就创建以RNA为中心的预防及精准医疗平台建立战略合作伙伴关系，并涵盖共同开发、临床试验及注册以及销售及分销。此新型及以 RNA为中心的预防及精准医疗平台将令全球机构于把握及拓展区域机遇时与公司及沃森合作，同时令公司与沃森战略性进入东盟及特定国际市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4588","RNA","BK4585","02629","BK4505","BK1161","IE0009354923.USD"],"gpt_icon":0},{"id":"2583742005","title":"Korro Bio的RNA编辑药物例临床结果不佳，引发裁员，诺和诺德暂停合作 | 2025Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2583742005","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583742005?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:13","pubTimestamp":1763115231,"startTime":"0","endTime":"0","summary":"诺和诺德与Korro的合作协议暂停一年，用于重新评估伙伴关系。公告后，Korro Bio股价暴跌近80%，市值大幅缩水；多家投行下调评级。11月13日，Korro Bio公布了其最新财务业绩，同时披露了重大临床挫折。报道指出，作为应对措施，Korro Bio宣布进行公司重组，包括裁减约34%的员工。此次事件导致Korro Bio股价在11月13日开盘后暴跌近80%，从前一交易日收盘价大幅下滑。当天，Korro宣布第三季度末现金流为1.025亿美元，并计划通过裁员约34%来延长现金储备至2027年下半年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114181901a6f94906&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114181901a6f94906&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","LU0154236417.USD","BK4588","NVO","BK4139","IE00BKVL7J92.USD","BK4532","IE00BZ1G4Q59.USD","BK4505","LU1093756168.USD","BK4585","RNA","LU1093756325.SGD","BK4007","BK4599","KRRO"],"gpt_icon":1},{"id":"1189450042","title":"周二关注股票：亚马逊、新纪元、联合健康、英伟达","url":"https://stock-news.laohu8.com/highlight/detail?id=1189450042","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189450042?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:02","pubTimestamp":1761642138,"startTime":"0","endTime":"0","summary":"亚马逊：这家科技公司计划自周二开始裁员多达3万名员工。亚马逊将在周四公布季度财报。然而，股价在盘后交易中下跌。新纪元能源将在今天上午公布财报，而谷歌母公司Alphabet则定于周三公布财报。联合健康、PayPal、皇家加勒比邮轮和联合包裹的财报也将于今天上午发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023251221.USD","SGXZ57979304.SGD","SGXZ51526630.SGD","IE0004445239.USD","LU2637428348.USD","LU2860962120.EUR","LU0985320562.USD","LU1633808545.USD","LU0107464264.USD","LU2237443549.SGD","LU2265009873.SGD","LU2125909759.SGD","IE000W1ABFV2.USD","LU0070302665.USD","LU1244550577.SGD","LU0823421416.USD","IE00B2B36J28.USD","BK4588","LU0742534661.SGD","LU2458330243.SGD","IE0009355771.USD","IE00BJJMRX11.SGD","IE00BD4GTW91.USD","LU0149725797.USD","LU0320765646.SGD","LU1934455194.USD","LU1929549753.HKD","LU0466842654.USD","LU0080751232.USD","3NVD.UK","LU0154236417.USD","LU0256863902.USD","LU0345769631.USD","LU0494093205.USD","IE00BZ9MQY76.HKD","LU0949170426.SGD","LU2054465674.USD","NEE","IE00BFXG0V08.USD","LU0130102774.USD","LU0157215616.USD","LU0070217475.USD","LU2505996681.GBP","LU2420271590.USD","LU1066051225.USD","IE0034235295.USD","LU1629891620.HKD","SNVD.UK","LU1571399168.USD","SGXZ23171101.USD","LU2360032135.SGD","LU2083900584.USD","LU0158827781.USD","LU0690374961.EUR","LU0672654240.SGD","LU1917777945.USD","LU0130517989.USD","LU2360106780.USD","IE00BWXC8680.SGD","HK0000320223.HKD","LU1883866441.USD","LU2087625088.SGD","LU0006306889.USD","PYPL","LU2931357623.SGD","LU2272731865.HKD","LU0323591593.USD","LU1323610961.USD","LU1235294995.USD","LU1935042991.SGD","BK4579","BK4139","BK4596","LU1923622291.USD","LU2430703251.USD","LU0211326755.USD","LU2271345857.HKD","LU0312595415.SGD","IE00BFTCPJ56.SGD","LU0097036916.USD","LU2065170008.USD","IE00BJJMRY28.SGD","LU0175139822.USD","LU1712237335.SGD","LU2452424414.USD","LU1674673691.USD","LU2764262908.HKD","LU0211327993.USD","LU2213496289.HKD","LU2087621335.USD","LU1003077747.HKD","IE00BMG7P926.USD","IE0034235188.USD","LU1894683348.USD","LU1093756325.SGD","LU0882574139.USD","LU1923622614.USD","LU0354030438.USD","LU1121112475.USD","IE00B3M56506.USD","LU0061474705.USD","LU0786609619.USD","IE00BGHQF417.EUR","LU2125909593.SGD","IE00BKDWB100.SGD","LU0266013472.USD","AMZN","LU1935043536.SGD","LU0198837287.USD","LU1429558221.USD","LU0345768740.USD","LU0882574055.USD","LU0345768153.USD","SG9999018865.SGD","LU2089284900.SGD","LU2413666699.HKD","BK4604","SG9999014898.SGD","LU1267930573.SGD","LU1861220207.SGD","IE000M9KFDE8.USD","LU2125154778.USD","SG9999001176.USD","LU2468319806.SGD","LU2491050071.SGD","IE00BZ199S13.USD","LU0784385840.USD","LU0724617625.USD","BK4131","LU1548497426.USD","LU1732799900.SGD","IE00BMPRXN33.USD","LU0784384876.USD","LU0426412945.USD","LU0061475181.USD","LU0557290698.USD","LU1201861249.SGD","IE00BMG7P694.USD","BK4077","LU0661504455.SGD","LU2394011477.USD","LU0823421333.USD","IE0009G5SDU7.USD","SGXZ81514606.USD","HK0000306685.HKD","LU2362541513.USD","LU2065169927.USD","LU0251132253.USD","BK4524","LU0211331839.USD","LU1935042488.USD","SG9999014906.USD","BK4554","LU2089984988.USD","LU2462611646.USD","SG9999015978.USD","IE00BN29S564.USD","LU0354030511.USD","LU1815336760.USD","LU2324357040.USD","BK4227","BK4547","LU0708994859.HKD","IE00B1XK9C88.USD","LU2487616109.SGD","NVDD","LU0390134368.USD","BK4191","LU2462157665.USD","LU2237443622.USD","IE00BFSS7M15.SGD","SG9999015358.SGD","IE00BJTD4N35.SGD","LU0158827948.USD","LU1670627923.USD","IE0002270589.USD","LU0289739699.SGD","LU2750360641.GBP","LU2505996509.AUD","LU2430703095.HKD","LU1316542783.SGD","LU0203347892.USD","LU0162691827.USD","LU0082616367.USD","LU0203202063.USD","LU1043141123.HKD","BK4534","LU0094547139.USD","LU2746668974.SGD","IE000YTNTUN2.SGD","LU0353189680.USD","SG9999001077.SGD","IE00B19Z9P08.USD","LU0823434583.USD","LU0251142724.SGD","LU0127658192.USD","LU1069347547.HKD","IE00B19Z9Z06.USD","LU0079474960.USD","LU0048584097.USD","LU0056508442.USD","LU0109392836.USD","LU1116320901.HKD","LU2125154935.USD","BK4606","LU0256863811.USD","LU0689626769.HKD","LU2168563687.JPY","IE0002141913.USD","LU1989764748.USD","BK4587","LU0122379950.USD","LU2322448791.USD","LU2362541273.HKD","SG9999014542.SGD","IE00BK4W5L77.USD","LU0957808578.USD","LU2111349929.HKD","LU0211328371.USD","LU2097344431.USD","LU1861558580.USD","LU2275660780.HKD","LU0976567544.SGD","WHR","LU2471134796.USD","LU1119994496.HKD","LU1244550494.USD","LU1791710582.SGD","IE000ITXATA3.USD","SG9999017495.SGD","LU2458330169.SGD","LU1366192091.USD","LU2463028550.USD","LU0724618433.USD","LU0210536198.USD","LU2211814178.USD","LU0251131958.USD","LU0345769128.USD","LU1084165304.USD","LU0170899867.USD","LU1069344957.HKD","LU2249611893.SGD","LU0889566641.SGD","LU1951198990.SGD","LU2361044865.SGD","SGXZ31699556.SGD","LU2023250843.SGD","BK4532","LU1496350171.SGD","LU0472753341.HKD","LU0889565833.HKD","LU0433182093.SGD","LU2272731600.USD","LU0124676726.USD","BK4576","HK0000306701.USD","BK4122","IE00BJJMRZ35.SGD","LU0787776722.HKD","LU0795875169.SGD","BK4543","SG9999015952.SGD","LU1974910355.USD","LU2089985449.USD","BK4561","IE00B3S45H60.SGD","LU2357305700.SGD","LU1868836757.USD","HK0000320264.USD","LU2133065610.SGD","BK4612","LU2404859741.USD","BK4574","LU0208291251.USD","LU1803068623.USD","LU2756315664.SGD","LU1064131342.USD","LU1861559042.SGD","LU0096364046.USD","LU2543165471.USD","LU2498475776.HKD","LU0289739343.SGD","LU2063271972.USD","IE00B5TLWC47.USD","BK4551","LU2500361329.USD","SG9999015986.USD","IE00B3CCJ633.GBP","BK4567","USAW.SI","IE00B894F039.SGD","LU0788109477.HKD","IE00BJT1NW94.SGD","LU0068578508.USD","LU2433249047.HKD","IE00BFSS8Q28.SGD","LU0689472784.USD","LU0965509283.SGD","NVDS","LU2506951792.HKD","LU2264538146.SGD","LU0114720955.EUR","LU0345774391.USD","LU2237438978.USD","BK4007","GB00B4LPDJ14.GBP","LU0823414551.USD","LU0215105999.USD","LU0069063385.USD","LU0320765489.SGD","LU0943347566.SGD","NVIW.SI","IE0009356076.USD","LU2237443978.SGD","LU0476273544.USD","LU0868494708.USD","LU2108987350.USD","LU1914381329.SGD","BK4614","IE00BQXX3D17.EUR","IE00BSNM7G36.USD","SG9999002232.USD","IE00BN8TJ469.HKD","LU1023059063.AUD","LU1778281490.HKD","IE00B19Z9505.USD","LU1066053197.SGD","LU0345774631.USD","LU2097344357.USD","LU1621768206.USD","LU0444971666.USD","LU2491049909.HKD","LU1988902786.USD","IE00B19Z3B42.SGD","LU1674673428.USD","LU1923623000.USD","LU0683600562.USD","LU1059921491.USD","LU1435385759.SGD","NVS","LU1621767810.EUR","LU1035775433.USD","LU0823416689.USD","BK4581","LU0738911758.USD","LU0011850046.USD","LU0417517546.SGD","LU2317271919.USD","SG9999014880.SGD","LU2290526834.HKD","LU2089283258.USD","LU0072462426.USD","RCL","IE00BD6J9T35.USD","LU1861220033.SGD","LU1291159041.SGD","IE00BLSP4239.USD","IE00BMG7P587.USD","IE00B1BXHZ80.USD","LU0708995401.HKD","LU2168564065.EUR","IE00B3SWFQ91.USD","IE00BHPRN162.USD","LU1280957306.USD","LU1951200564.SGD","IE00B4JS1V06.HKD","LU0310799852.SGD","LU0314104364.USD","IE00B19Z8W00.USD","LU2471134952.CNY","LU2750360997.AUD","SG9999014575.USD","IE00BK4W5M84.HKD","IE00BLSP4452.SGD","LU0511384066.AUD","LU0553294199.USD","LU1093756168.USD","LU0203201768.USD","LU1267930227.SGD","BK4597","BK4503","LU2404859667.USD","LU0432979614.USD","LU2491050154.USD","IE00BBT3K403.USD","LU1242518857.USD","LU0265550946.USD","LU1303367103.USD","LU1366333091.USD","LU2168564495.EUR","LU2023250330.USD","BK4548","BK4566","LU1037948541.HKD","LU1852331112.SGD","LU1221951046.USD","LU0029864427.USD","LU1992135399.USD","LU0965509010.AUD","LU1868837300.USD","LU0545039389.USD","LU1732800096.USD","LU2092627202.USD","LU1691799644.USD","LU2098885051.SGD","LU1978683503.SGD","LU1839511570.USD","LU2413666426.HKD","LU1301847155.USD","LU0820561909.HKD","UPS","IE00B29SXL02.USD","LU1861217088.USD","LU0348723411.USD","LU0528227936.USD","LU1854103824.USD","LU2238339852.HKD","LU0274383776.USD","LU2294711713.HKD","NVD","LU1791807156.HKD","LU0234570918.USD","LU2279689827.SGD","BK4505","LU1506573853.SGD","LU1551013342.USD","NVDS.UK","BK4220","LU1074936037.SGD","LU1989772923.USD","LU0795875086.SGD","GB00BDT5M118.USD","LU2326559502.SGD","LU1267930813.SGD","LU1585245621.USD","LU1880398471.USD","LU2242650005.HKD","LU0345770308.USD","BK4559","LU0225283273.USD","IE00B19Z8X17.USD","BK4525","LU0792757196.USD","LU2247934214.USD","LU2125909916.SGD","LU0289960550.SGD","LU1621767737.EUR","LU1267930490.SGD","LU0234572021.USD","LU0057025933.USD","LU0096362180.USD","SG9999015945.SGD","LU2322448957.HKD","LU0106831901.USD","IE00BQXX3F31.USD","LU0496365809.HKD","LU2250418816.HKD","LU1066051498.USD","IE00BMPRXQ63.HKD","LU0640476718.USD","LU2065171311.SGD","LU1983299246.USD","LU1430594728.SGD","LU1791710400.SGD","LU1992135472.HKD","LU0353189763.USD","LU2125909247.SGD","GOOG","LU1489326972.SGD","LU2272731782.SGD","LU0878866978.SGD","LU0477156953.USD","LU1267930730.SGD","LU0265550359.USD","LU0289941410.SGD","NVDA","LU0642271901.SGD","LU1127390331.HKD","BK4578","BK4154","LU0949170772.SGD","LU1145028129.USD","IE00BD4GTT62.SGD","LU2403377893.USD","IE00BJLML261.HKD","LU0302445910.USD","LU1861215975.USD","LU0081259029.USD","LU2298064838.USD","LU2357125470.USD","LU2746668461.USD","LU1935043023.USD","LU0320765059.SGD","LU1153585028.USD","LU2211815571.USD","LU0823414478.USD","LU0347712357.USD","LU1670628061.USD","LU1699723380.USD","LU2168564149.EUR","LU2602419157.SGD","LU0053666078.USD","NVDU","USJW.SI","LU2381873111.SGD","LU0912757837.SGD","LU0426417589.USD","LU1551013425.SGD","LU2237443465.HKD","NVDY","LU0128525689.USD","LU2471134879.HKD","IE00BMG7P819.SGD","LU1261432733.SGD","LU0648001328.SGD","LU1201861165.SGD","LU0868494617.USD","LU0187121727.USD","LU2552382132.HKD","LU2384288077.EUR","IE0034235303.USD","IE00BZ1G4Q59.USD","SG9999000418.SGD","BK4585","LU0957791311.USD","LU1868836914.USD","LU1116320737.USD","IE00BMG7P702.HKD","LU0820562030.AUD","BK4538","LU0994945656.USD","SG9999014559.SGD","2NVD.UK","LU1854104046.USD","LU1046421795.USD","IE000KEQY171.SGD","LU0203345920.USD","IE0004086264.USD","LU2430703178.SGD","RNA","LU0128525929.USD","LU0985489474.SGD","NVDX","LU0072461881.USD","LU2237957811.SGD","LU1037948897.HKD","LU1057294990.SGD","LU0109391861.USD","LU2106854487.HKD","BK4598","LU2168564222.USD","LU0861579265.USD","LU2471134523.USD","LU2112291526.USD","LU0823434740.USD","LU2237443382.USD","LU0965509101.SGD","LU1720051017.SGD","LU2461242641.AUD","LU2361044949.HKD","LU0979878070.USD","SG9999001424.SGD","LU0342679015.USD","LU0964807845.USD","BK4553","LU2077746001.SGD","LU0130103400.USD","BK4573","SG9999013999.USD","IE00BQXX3C00.GBP","LU0310800379.SGD","LU1861127337.USD","LU2764263039.SGD","LU1061106388.HKD","LU1868836591.USD","IE00BDRTCR15.USD","LU0130518102.USD","LU1718418525.SGD","IE00BJTD4V19.USD","LU1496350502.SGD","LU1989764664.SGD","BK4535","LU0289961442.SGD","NVD3.UK","IE00B2PGVK34.USD","LU2065171402.SGD","LU1934455863.HKD","BK4592","LU2237443895.HKD","LU2048586759.USD","IE00B775SV38.USD","UNH","LU1804176565.USD","LU2417539215.USD","LU0267386448.USD","LU1939255532.USD","LU1983260115.SGD","IE0004091025.USD","BK4081","LU0210528500.USD","IE0004445015.USD","LU0238689110.USD","LU0314106906.USD","LU1232071149.USD","IE0003U64NQ7.SGD","LU0820561818.USD","SG9999001176.SGD","LU0316494557.USD","LU1814569148.SGD","IE00BMPRXR70.SGD","LU1642822529.SGD","LU2347655156.SGD","BBBY","LU0048573561.USD","IE00B7SZLL34.SGD","LU0345770993.USD","IE00B775H168.HKD","BK4106","LU1821325948.USD","LU1242518931.SGD","LU1803068979.SGD","LU0052756011.USD","LU0477156797.USD","LU2456880835.USD","LU1623119135.USD","IE00BKVL7J92.USD","SG9999018857.SGD","SG9999004303.SGD","LU0690374615.EUR","GB00B4QBRK32.GBP","IE0005OL40V9.USD","IE00B4YYXB79.USD","LU1934455277.USD","IE00BYQQ9H92.USD","LU0965508806.USD","LU2237957902.USD","LU2896262040.SGD","BK4527","LU2028103732.USD","BK4533","BK4141","LU1621768115.EUR","LU0308772762.SGD","LU1668664300.SGD","LU0784385170.HKD","BK4550","LU2552382058.USD","NVD2.UK","LU2286300806.USD","LU0211326839.USD","LU2092937148.SGD","BK4529","LU2097829019.USD","LU1162221912.USD","LU2756315318.SGD","LU1720051108.HKD","BK4602","LU2473716301.USD","IE00BD4GTV84.USD","SG9999014914.USD","LU0058720904.USD","LU0210533765.USD","LU1894683264.USD","LU2552382215.SGD","LU1815333072.USD","GOOGL","LU1989771016.USD","BK4517","LU0106261372.USD","LU1989772840.SGD","LU0061474960.USD","LU1721428933.USD","LU1196500208.SGD","LU2764263203.CNY","LU2592432038.USD","BK4605","LU0719512351.SGD","SGXZ99366536.SGD","LU0444973449.USD","IE00B7KXQ091.USD","LU0456855351.SGD","IE00B5949003.HKD","BK4514","LU1868837136.USD","BK4178","LU1935042215.USD","LU0823411888.USD","LU1066051811.HKD","SG9999002224.SGD","NVDL","BK4142","LU2023250504.SGD","BK4549","IE00BFXG1179.USD","LU2298322129.HKD","LU2360107671.USD","LU1244550221.USD","SG9999015341.SGD","LU0124384867.USD","LU2191332357.HKD","LU2360107168.USD","LU2720916845.USD","SG9999014567.USD","LU0077335932.USD","LU2242649171.HKD","LU0276348264.USD","LU2236285917.USD","LU0648000940.SGD","IE00B19Z3581.USD","LU1221951129.SGD","LU1035773651.USD","LU1032955483.USD","LU1823568750.SGD","IE00BKPKM429.USD","IE00B29SXK94.USD","BK4507","LU0784383803.USD","BK4608","IE00BDCRKT87.USD","LU0980610538.SGD","LU1043141396.HKD","LU2244417387.USD","LU0310800965.SGD","LU2361045086.USD","LU2362540622.SGD","IE00B4R5TH58.HKD","LU0942090050.USD","LU1880398554.USD","IE00BYXW3230.USD"],"gpt_icon":1},{"id":"1113634984","title":"Avidity Biosciences, Inc.：RBC将其目标评级从“跑赢大盘”下调至“行业表现”，并将目标价从61美元上调至72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113634984","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113634984?lang=zh_cn&edition=full","pubTime":"2025-10-28 13:11","pubTimestamp":1761628270,"startTime":"0","endTime":"0","summary":"Avidity Biosciences, Inc.：RBC将其目标评级从“跑赢大盘”下调至“行业表现”，并将目标价从61美元上调至72美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RNA","BK4139","BK4505","BK4588"],"gpt_icon":0},{"id":"1187667451","title":"Avidity Biosciences Inc ：Leerink Partners 将评级从“跑赢大盘”下调至“市场表现”；目标价格上调至72美元，从65美元提高","url":"https://stock-news.laohu8.com/highlight/detail?id=1187667451","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187667451?lang=zh_cn&edition=full","pubTime":"2025-10-27 22:44","pubTimestamp":1761576252,"startTime":"0","endTime":"0","summary":"Avidity Biosciences Inc ：Leerink Partners 将评级从“跑赢大盘”下调至“市场表现”；目标价格上调至72美元，从65美元提高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","BK4588","RNA","BK4139"],"gpt_icon":0},{"id":"1181059515","title":"诺华首席执行官表示公司计划与美国FDA讨论对Avidity纤维肌痛症治疗的加速审批潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1181059515","media":"美股速递","labels":["executive","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181059515?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:49","pubTimestamp":1761569351,"startTime":"0","endTime":"0","summary":"诺华首席执行官表示公司计划与美国FDA讨论对Avidity纤维肌痛症治疗的加速审批潜力","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4505","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"1175719093","title":"Avidity Biosciences- 在特定情况下合并与诺华终止时，公司需向诺华支付4.5亿美元的终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1175719093","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175719093?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:32","pubTimestamp":1761564729,"startTime":"0","endTime":"0","summary":"Avidity Biosciences- 在特定情况下合并与诺华终止时，公司需向诺华支付4.5亿美元的终止费","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"03493874a4eadea936a603e5a022bfa9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","BK4139","BK4585","RNA"],"gpt_icon":0},{"id":"1143719887","title":"Avidity Biosciences Inc：Bernstein下调评级至市场表现，从跑赢大盘调整至$72目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1143719887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143719887?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:08","pubTimestamp":1761556091,"startTime":"0","endTime":"0","summary":"Avidity Biosciences Inc：Bernstein下调评级至市场表现，从跑赢大盘调整至$72目标价，上调目标价格至$72，从$52上调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","RNA","BK4505","BK4139"],"gpt_icon":0},{"id":"2578374669","title":"120亿美元拿下“罕见病专家”Avidity，医药巨头诺华同意历史上最大笔收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2578374669","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578374669?lang=zh_cn&edition=full","pubTime":"2025-10-27 08:31","pubTimestamp":1761525108,"startTime":"0","endTime":"0","summary":"诺华以120亿美元收购罕见病生物技术公司Avidity，创公司十多年最大收购案，溢价46%。Avidity三种在研药物预计2030年前上市，峰值年销售额可达数十亿美元，将助力诺华应对专利悬崖。此次交易将诺华2024-2029年复合年增长率从5%提升至6%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3757939","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d983b7f77c56e019b628a01bf1a49d41","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3757939","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"120亿美元拿下“罕见病专家”Avidity，医药巨头诺华同意历史上最大笔收购","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","NVS"],"gpt_icon":1},{"id":"2577591811","title":"石药集团(01093)：SYH2061注射液(双链小干扰RNA药物)在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2577591811","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577591811?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:33","pubTimestamp":1761298432,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团自主研发的化学1类新药SYH2061注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面均优于同类型siRNA产品，展现出药物作用效果持久、安全性良好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008369823.USD","BK1191","LU1807302812.USD","IE00B5MMRT66.SGD","LU0140636845.USD","BK4139","01093","LU0072913022.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1008478684.HKD","LU0315179316.USD","LU1226287875.USD","SG9999004220.SGD","LU1328277881.USD","LU1993786604.SGD","IE00B031HY20.USD","LU0314109678.HKD","IE00B543WZ88.USD","LU0067412154.USD","LU2039709279.SGD","BK1521","RNA","LU1152091754.HKD","IE00BZ08YR35.GBP","LU1960683339.HKD","BK4588","LU1226287792.SGD","LU0880133367.SGD","BK4505","LU1226288253.USD","BK1515","IE00BZ08YS42.EUR","LU1226287529.USD","IE0008368742.USD","LU0501845795.SGD","LU1226288170.HKD","LU1813983027.USD","LU0326950275.SGD","BK4585","LU1152091168.USD"],"gpt_icon":0},{"id":"1165649055","title":"Avidity Biosciences宣布Del-Zota治疗DMD44获得美国FDA积极的生物制品许可申请预备会议反馈，计划于2026年第一季度提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1165649055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165649055?lang=zh_cn&edition=full","pubTime":"2025-10-13 21:01","pubTimestamp":1760360483,"startTime":"0","endTime":"0","summary":"Avidity Biosciences宣布，该公司针对Del-Zota治疗DMD44适应症与美国食品药品监督管理局(FDA)举行的生物制品许可申请预备会议取得积极进展。公司计划于2026年第一季度正式提交相关申请。\n这一积极的监管里程碑为Del-Zota在DMD44治疗领域的后续开发奠定了重要基础，标志着该疗法向商业化迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","BK4139","RNA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aviditybiosciences.com","stockEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":0.015},{"period":"3month","weight":0.7341},{"period":"6month","weight":1.4509},{"period":"1year","weight":1.2118},{"period":"ytd","weight":1.4711}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avidity Biosciences, Inc.是根据特拉华州法律于2012年11月13日成立的。该公司是一家生物制药公司。公司开创了一种新型的基于寡核苷酸的疗法，称为抗体寡核苷酸缀合物（AOC），旨在克服寡核苷酸疗法的当前局限性，以治疗多种严重的疾病。该公司利用其专有的AOC平台来设计，策划和开发结合单克隆抗体（mAbs）的组织选择性和寡核苷酸疗法的精确性的疗法，以访问以前无法吸收的组织和细胞类型，并更有效地针对疾病的潜在遗传驱动因素。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.029515},{"month":2,"riseRate":0.6,"avgChangeRate":0.100374},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00029},{"month":4,"riseRate":0.4,"avgChangeRate":-0.058331},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018927},{"month":6,"riseRate":0.8,"avgChangeRate":0.113151},{"month":7,"riseRate":0.5,"avgChangeRate":0.027674},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073003},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048121},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.000506},{"month":11,"riseRate":0.666667,"avgChangeRate":0.096576},{"month":12,"riseRate":0.666667,"avgChangeRate":0.110004}],"exchange":"NASDAQ","name":"Avidity Biosciences, Inc.","nameEN":"Avidity Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avidity Biosciences, Inc.(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avidity Biosciences, Inc.(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avidity Biosciences, Inc.,RNA,Avidity Biosciences, Inc.股票,Avidity Biosciences, Inc.股票老虎,Avidity Biosciences, Inc.股票老虎国际,Avidity Biosciences, Inc.行情,Avidity Biosciences, Inc.股票行情,Avidity Biosciences, Inc.股价,Avidity Biosciences, Inc.股市,Avidity Biosciences, Inc.股票价格,Avidity Biosciences, Inc.股票交易,Avidity Biosciences, Inc.股票购买,Avidity Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avidity Biosciences, Inc.(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avidity Biosciences, Inc.(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}